Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23,09:00–17:30
CNS Novel Drug R&D Session
Stay tuned
Conference Planning
Fei Guo:Founder, Hanshu Biotechnology
Dawei Yuan:Founder, Chairman and General Manager, Beijing Quark Pharmaceutical Group
Huaqiong Shen:Founder & CEO, Neushen Pharmaceuticals
Conference Hosting
Rui Huang:Deputy General Manager, Hanshu Biotechnology
09:00-09:05 Message
Yutian Wang:Professor, Shangsi Neuroscience Center, Fudan University;Fellow of the Royal Society of Canada;Founder & Chairman, Purui Pharmaceuticals
09:05-09:30 Memory Reactivation Underlies Experience-Dependent Adaptive Regulation of Sleep
Yi Zhong:Professor, School of Life Sciences, Tsinghua University; Principal Investigator, Tsinghua-IDG/McGovern Institute for Brain Research; Founder, Chairman & Chief Scientist, Beijing Joekai Biotechnology
09:30-09:45 Research and Development of New Molecular Entity (NME) Drugs for Schizophrenia
Jingwei Tian:Executive Vice President of R&D, Luye Pharma Group; Dean, School of Pharmacy, Yantai University
09:45-10:00 PRODEGRE ATLAS – A Protein Degradation Innovation Platform to Enable Breakthrough Therapies for CNS Disorders
Shen Tan:Co-founder & CEO, Purui Pharmaceuticals
10:00-10:15 Research Progress of the AMCDx Platform (Cyclodextrin Analogues) in the CNS Field
Youmao Qi:Chairman, Omer Pharmaceuticals; Director of the Academician Workstation; Chief Scientist
10:15-10:35 Break
10:35-10:50 Discovery and Development of a Novel Non-Opioid Potent Analgesic Agent with Dual Target Mechanism
Xijun SHENG:Head of Innovative Research Center, YiChang Humanwell Pharmaceutical Co.,Ltd.
10:50-11:05 Frontier Technology in Innovative CNS Drug Development
Isaac Cheng:VP Research of suntec medical
11:05-11:20 Disease-Modifying Therapy for Parkinson's Disease
Yang Song:CEO &CMO ofHygtia Therapeutics
11:20-12:10 Roundtable: The Future of CNS New Drug R&D
Fei Guo(Host):Founder, Hanshu Biotechnology
Qun Fang:Chief Scientific Officer (CSO), Yisi Biotechnology; Head of Brain Science Innovation R&D Center
Qun Li:General Manager, Saipute
Bingjie Wang:Chief Business Officer (CBO), Iongen Therapeutics Co., Ltd.
Deqiang Niu: Co-founder & CEO of Kehui Zhihao (COHITON)
12:10-13:30 Lunch Break
Conference Hosting
David.yuan:Chairman, Quark Pharmaceutical Group
13:30-13:50 The Path to Clinical Translation of Innovative Biopharmaceuticals – Opportunities, Challenges, and Collaboration
Tianmei Si:Vice President, Peking University Sixth Hospital; Deputy Director, National Institute of Mental Health
13:50-14:10 Research on JAK-STAT Therapy for Neurodegenerative Diseases
Xinyuan Fu:Founder of GenEros Biopharma; Director of the Institute of Immunological Inflammation, West China Hospital of Sichuan University; Director of the Laboratory of Human Diseases and Immunotherapy
14:10-14:30 Director of Clinical Research Center, Shanghai Mental Health Center; Executive Director of National Drug Clinical Trial Institution
Huafang Li : Director of the Clinical Research Center, Shanghai Mental Health Center; Executive Director of the National Drug Clinical Trial Institution
14:30-14:45 Expanding Extrahepatic Applications of Oligonucleotide Therapeutics – Research Progress in CNS Diseases
Shan Gao:Senior Vice President & Chief Scientific Officer (CSO), Ribo Life Science
14:45-15:00 Medical Uses and Market Prospects of Modified Psychedelics – Perspectives from the FDA's New Guidance and Trump's Executive Order
Joan Shen:Founder & CEO, NeuShen Therapeutics
15:00-15:15 Universal iPSC-Derived Cell Therapy for Neurological Injury Disorders
Jing Fan:Founder & CEO, Hopstem Biosciences
15:15-15:35 Break
15:35-15:50 Preliminary Validation of iPSC-Derived Therapies for CNS Disorders Based on the SISBAR Core Technology Platform
Lanlin Wu:CEO, Unicell Biotechnology
15:50-16:05 Clinical Study on Deep Cervical Lymphatic Venous Anastomosis for Alzheimer's Disease
Ping Luan:Director and Chief Scientist of the National Advanced Cognitive Center (Department of Alzheimer's Disease Clinical Research Center, Guangdong Second Provincial General Hospital )
16:05-16:20 Development and Global Commercialization Pathway of QP001 Injection
Sen Yu:Vice President, Qingpu Biopharma
16:20-16:35 Mouse Models in Neuroscience: Bridging Efficacy to the Clinic - A CriticalPiece in Accelerating CNS Drug Translation
Rikki FENG:Chief Scientist, Neuroscience Pipeline, GemPharmatech
16:35-16:50 Overcoming the Blood-Brain Barrier with Theranostic Bubbles and Ultrasound
Mr. Michael Paumen:WellThera Director
16:50-17:30 Roundtable: The Globalization Path of China's CNS Innovative Drugs
Xiaochun Huang(Host):VP,Beijing Quark Pharmaceutical Group
Yongjiang Hei:Founder, Huisibo Biopharma
Jun Tan:Co-founderand Chief Scientific Advisor ofAnyu Biotechnology (Hangzhou) Co., Ltd
William:Former General Manager, Joekai Biotechnology
Mengqi Fan:Mengqi Fan: CEO, Mabwell Biosciences, Chairman SA